KR20230097034A - 암을 치료하기 위한 제약 조성물 및 그의 사용 방법 - Google Patents

암을 치료하기 위한 제약 조성물 및 그의 사용 방법 Download PDF

Info

Publication number
KR20230097034A
KR20230097034A KR1020237014585A KR20237014585A KR20230097034A KR 20230097034 A KR20230097034 A KR 20230097034A KR 1020237014585 A KR1020237014585 A KR 1020237014585A KR 20237014585 A KR20237014585 A KR 20237014585A KR 20230097034 A KR20230097034 A KR 20230097034A
Authority
KR
South Korea
Prior art keywords
effective amount
venetoclax
decitabine
cedazuridine
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237014585A
Other languages
English (en)
Korean (ko)
Inventor
아람 오가네시안
김-히엔 다오
해롤드 키어
Original Assignee
오츠카 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오츠카 세이야쿠 가부시키가이샤 filed Critical 오츠카 세이야쿠 가부시키가이샤
Publication of KR20230097034A publication Critical patent/KR20230097034A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020237014585A 2020-10-29 2021-10-27 암을 치료하기 위한 제약 조성물 및 그의 사용 방법 Pending KR20230097034A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063107010P 2020-10-29 2020-10-29
US63/107,010 2020-10-29
PCT/US2021/056809 WO2022093930A1 (en) 2020-10-29 2021-10-27 Pharmaceutical compositions and methods of using the same for treating cancer

Publications (1)

Publication Number Publication Date
KR20230097034A true KR20230097034A (ko) 2023-06-30

Family

ID=81384423

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237014585A Pending KR20230097034A (ko) 2020-10-29 2021-10-27 암을 치료하기 위한 제약 조성물 및 그의 사용 방법

Country Status (10)

Country Link
US (1) US12697347B2 (enExample)
EP (1) EP4237094A4 (enExample)
JP (2) JP2023548303A (enExample)
KR (1) KR20230097034A (enExample)
CN (2) CN122182592A (enExample)
AU (1) AU2021369508B2 (enExample)
CA (1) CA3188316A1 (enExample)
MX (1) MX2023003305A (enExample)
TW (1) TW202227096A (enExample)
WO (1) WO2022093930A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023548303A (ja) 2020-10-29 2023-11-16 大塚製薬株式会社 癌を処置する為の医薬組成物及びその使用方法
AU2024265282A1 (en) * 2023-05-02 2025-12-18 Taiho Pharmaceutical Co., Ltd. Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2708264C (en) 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
US9834576B2 (en) 2013-10-29 2017-12-05 Otsuka Pharmaceutical Co., Ltd. Synthetic route to 2′-deoxy-2′,2′-difluorotetrahydrouridines
US10683552B2 (en) 2014-11-25 2020-06-16 Presidents And Fellows Of Harvard College Clonal haematopoiesis
US11224610B2 (en) 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
SG11202108523UA (en) * 2019-03-25 2021-09-29 Otsuka Pharma Co Ltd Antitumor composition
MX2022005811A (es) 2019-11-13 2022-06-08 Taiho Pharmaceutical Co Ltd Sal novedosa de compuesto de terfenilo.
WO2021113688A1 (en) 2019-12-05 2021-06-10 Sumitomo Dainippon Pharma Oncology, Inc. Combination therapies for treatment of myelodysplastic syndrome
EP4090335A1 (en) 2020-01-17 2022-11-23 Novartis AG Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
LT4069254T (lt) 2020-02-25 2024-10-10 Otsuka Pharmaceutical Co., Ltd. Kietos geriamosios vaisto formos, apimančios decitabiną ir cedazuridiną
JP2023548303A (ja) 2020-10-29 2023-11-16 大塚製薬株式会社 癌を処置する為の医薬組成物及びその使用方法
JP2024521824A (ja) 2021-05-27 2024-06-04 ヴァンダービルト ユニヴァーシティ マクロライド化合物
MX2024003537A (es) 2021-09-21 2024-05-03 Otsuka Pharma Co Ltd Metodos de tratamiento de los sindrome mielodisplasico con decitabina y cedazuridina.

Also Published As

Publication number Publication date
JP2023548303A (ja) 2023-11-16
CN116018145A (zh) 2023-04-25
TW202227096A (zh) 2022-07-16
CA3188316A1 (en) 2022-05-05
AU2021369508B2 (en) 2026-07-09
US20230405037A1 (en) 2023-12-21
US12697347B2 (en) 2026-08-04
WO2022093930A1 (en) 2022-05-05
JP2026083415A (ja) 2026-05-19
MX2023003305A (es) 2023-04-13
AU2021369508A1 (en) 2023-03-02
CN122182592A (zh) 2026-06-12
EP4237094A4 (en) 2024-07-10
EP4237094A1 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
CA2845806C (en) Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
JP7742841B2 (ja) デシタビンとセダズリジンとの組み合わせの固形経口剤形
JP2026083415A (ja) 癌を処置する為の医薬組成物及びその使用方法
CN104519878A (zh) 用于治疗顽固性或难治性抑郁症的艾氯胺酮
US20230122664A1 (en) Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
JP2021514975A (ja) サイクリン依存性キナーゼ阻害剤およびｂｅｔ−ブロモドメイン阻害剤の組合せ
CN104244952A (zh) 组蛋白脱乙酰酶抑制剂与帕唑帕尼的组合及其用途
WO2023201338A1 (en) Combination therapy comprising a mat2a inhibitor and a parp inhibitor
CA3232623A1 (en) Methods of treating myelodysplastic syndromes with decitabine and cedazuridine
HK40084686A (en) Pharmaceutical compositions and methods of using the same for treating cancer
CA3163122C (en) Combination decitabine and cedazuridine solid oral dosage forms
HK40105549A (en) Methods of treating myelodysplastic syndromes with decitabine and cedazuridine
HK40085734A (en) Solid oral dosage forms of combination of decitabine and cedazuridine
HK40082478A (en) Solid oral dosage forms comprising decitabine and cedazuridine
HK40082478B (en) Solid oral dosage forms comprising decitabine and cedazuridine
EA045934B1 (ru) Комбинированные твердые пероральные лекарственные формы децитабина и цедазуридина
HK40078096A (en) Methods of treating lsd1-related diseases and disorders with lsd1 inhibitors
MXPA01002673A (en) Antiviral combinations

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902